An inverse correlation was found between AGXT expression and liver triglyceride content 10
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 69(4), 10.26402/jpp.2018.4.09
Mutations of the tumor suppressor gene TP53 represent a common mutation in myeloid malignancies, occurring in 10-20% of patients with de novo myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) with profound negative impact on outcomes and a median overall survival (OS) of 6-12 months.31 Critically, the clonal burden of TP53 , that is the variant allele frequency (VAF) and/or allelic state of TP53 , is intimately tied with the clinical trajectory of these patients and is a robust, independent predictor of survival.74 Given the poor OS and lack of therapeutic options for TP53 mutant MDS/AML patients, a number of novel agents are being investigated in this patient group.8 Of these, APR-246 has evoked considerable excitement based on its robust clinical efficacy in combination with azacitidine in TP53 mutant MDS/AML patients.109 In this issue of Haematologica ,11 Maslah et al
Investing in proper moulds is worth it though
The waiver authority specifically allows states to include the costs of such projects as spend under its Medicaid State plan, which makes the spend eligible for federal matching support so that the state no longer has to fund the services entirely out of its general fund
